Vanguard Group Inc. Has $238.29 Million Position in Integra LifeSciences Holdings Corporation (IART)

Vanguard Group Inc. increased its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 116.7% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 5,656,048 shares of the life sciences company’s stock after buying an additional 3,046,488 shares during the period. Vanguard Group Inc. owned approximately 7.48% of Integra LifeSciences Holdings Corporation worth $238,289,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. FMR LLC raised its position in shares of Integra LifeSciences Holdings Corporation by 44.1% in the first quarter. FMR LLC now owns 7,615,884 shares of the life sciences company’s stock worth $320,857,000 after buying an additional 2,329,710 shares in the last quarter. Eagle Asset Management Inc. raised its position in shares of Integra LifeSciences Holdings Corporation by 138.0% in the first quarter. Eagle Asset Management Inc. now owns 1,185,041 shares of the life sciences company’s stock worth $49,925,000 after buying an additional 687,045 shares in the last quarter. Jennison Associates LLC acquired a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter worth $26,172,000. Victory Capital Management Inc. raised its position in shares of Integra LifeSciences Holdings Corporation by 79.2% in the first quarter. Victory Capital Management Inc. now owns 1,288,126 shares of the life sciences company’s stock worth $54,269,000 after buying an additional 569,223 shares in the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Integra LifeSciences Holdings Corporation by 97.8% in the first quarter. Fisher Asset Management LLC now owns 1,031,310 shares of the life sciences company’s stock worth $43,449,000 after buying an additional 509,980 shares in the last quarter. 89.70% of the stock is currently owned by institutional investors and hedge funds.

Shares of Integra LifeSciences Holdings Corporation (IART) traded down 1.18% during trading on Friday, hitting $55.04. The stock had a trading volume of 678,016 shares. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42. The company has a market cap of $4.16 billion, a PE ratio of 65.52 and a beta of 0.75. The stock has a 50 day moving average of $53.45 and a 200 day moving average of $46.43.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its earnings results on Wednesday, April 26th. The life sciences company reported $0.39 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by $0.01. The firm had revenue of $258.60 million during the quarter, compared to analysts’ expectations of $254.19 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.67% and a net margin of 6.66%. Integra LifeSciences Holdings Corporation’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.38 earnings per share. Equities analysts forecast that Integra LifeSciences Holdings Corporation will post $1.92 EPS for the current fiscal year.

WARNING: “Vanguard Group Inc. Has $238.29 Million Position in Integra LifeSciences Holdings Corporation (IART)” was published by BBNS and is the sole property of of BBNS. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/markets/vanguard-group-inc-acquires-3046488-shares-of-integra-lifesciences-holdings-corporation-iart-updated/1179686.html.

A number of equities analysts have weighed in on IART shares. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Integra LifeSciences Holdings Corporation in a research note on Monday, July 10th. ValuEngine lowered Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Jefferies Group LLC upped their target price on Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Oppenheimer Holdings, Inc. set a $54.00 target price on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research note on Monday, May 15th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $48.00 target price (up from $46.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $52.41.

In other Integra LifeSciences Holdings Corporation news, VP Glenn Coleman sold 13,865 shares of the business’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $45.91, for a total transaction of $636,542.15. Following the sale, the vice president now directly owns 18,519 shares of the company’s stock, valued at $850,207.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stuart Essig sold 135,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $49.90, for a total value of $6,736,500.00. Following the sale, the director now directly owns 2,077,475 shares in the company, valued at $103,666,002.50. The disclosure for this sale can be found here. Insiders sold 304,523 shares of company stock worth $14,812,988 over the last quarter. 21.40% of the stock is owned by company insiders.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Chris Sale Reaches 200 Strikeouts in Record Time
Chris Sale Reaches 200 Strikeouts in Record Time
Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.